Geneva, Feb. 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119061) titled 'Multicenter, Exploratory Study of Adebrelimab Combined with Apatinib in the Treatment of PD-1 Inhibitor-Pretreated (Progressive Unresectable) Hepatocellular Carcinoma' on Feb. 14.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Yantai Yuhuangding Hospital

Condition: Hepatocellular carcinoma

Recruitment Status: Not Recruiting

Phase: 4

Date of First Enrollment: 2026-02-14

Target Sample Size: Experimental group:30;

Countries of Recruitment: China

To know more, visit https://www.chictr.org.cn/showproj.html?proj=297222

Published by HT Digital Content Services with permission ...